Cargando…

Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A(2)

BACKGROUND: Bothropstoxin-I (BthTx-I) is a Lys49-phospholipase A(2) (Lys49-PLA(2)) from the venom of Bothrops jararacussu, which despite of the lack of catalytic activity induces myotoxicity, inflammation and pain. The C-terminal region of the Lys49-PLA(2)s is important for these effects; however, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambelli, Vanessa Olzon, Chioato, Lucimara, Gutierrez, Vanessa Pacciari, Ward, Richard John, Cury, Yara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303236/
https://www.ncbi.nlm.nih.gov/pubmed/28203248
http://dx.doi.org/10.1186/s40409-017-0099-6
Descripción
Sumario:BACKGROUND: Bothropstoxin-I (BthTx-I) is a Lys49-phospholipase A(2) (Lys49-PLA(2)) from the venom of Bothrops jararacussu, which despite of the lack of catalytic activity induces myotoxicity, inflammation and pain. The C-terminal region of the Lys49-PLA(2)s is important for these effects; however, the amino acid residues that determine hyperalgesia and edema are unknown. The aim of this study was to characterize the structural determinants for the Lys49-PLA(2)-induced nociception and inflammation. METHODS: Scanning alanine mutagenesis in the active-site and C-terminal regions of BthTx-I has been used to study the structural determinants of toxin activities. The R118A mutant was employed as this substitution decreases PLA(2) myotoxicity. In addition, K115A and K116A mutants – which contribute to decrease cytotoxicity – and the K122A mutant – which decreases both myotoxicity and cytotoxicity – were also used. The H48Q mutant – which does not interfere with membrane damage or myotoxic activity – was used to evaluate if the PLA(2) catalytic site is relevant for the non-catalytic PLA(2)-induced pain and inflammation. Wistar male rats received intraplantar injections with mutant PLA(2). Subsequently, hyperalgesia and edema were evaluated by the paw pressure test and by a plethysmometer. Native and recombinant BthTx-I were used as controls. RESULTS: Native and recombinant BthTx-I induced hyperalgesia and edema, which peaked at 2 h. The R118A mutant did not induce nociception or edema. The mutations K115A and K116A abolished hyperalgesia without interfering with edema. Finally, the K122A mutant did not induce hyperalgesia and presented a decreased inflammatory response. CONCLUSIONS: The results obtained with the BthTx-I mutants suggest, for the first time, that there are distinct residues responsible for the hyperalgesia and edema induced by BthTx-I. In addition, we also showed that cytolytic activity is essential for the hyperalgesic effect but not for edematogenic activity, corroborating previous data showing that edema and hyperalgesia can occur in a non-dependent manner. Understanding the structure-activity relationship in BthTx-I has opened new possibilities to discover the target for PLA(2)-induced pain.